Month: May 2022
New proof-of-concept approach offers faster, more accurate inferences about tumour populations. Excerpt from the Press Release: The prevalence of mutations in a tumour can provide clues about how the cancer has grown or evolved and how best to treat it. But making predictions about the evolution of mutated tumours using a single DNA sequenced biopsy…
Excerpt from the Press Release: The Ontario Brain Institute (OBI) has released a new set of clinical imaging modalities from a Province of Ontario Neurodevelopmental Network (POND) study for cohort of over 600 children and youth, some diagnosed with various neurodevelopmental disorders and others typically developing.This cleaned, standardized, and curated dataset is available for download on Brain-CODE, OBI’s neuroinformatics and analytics platform.…
ADI-001 exhibited robust in vitro and in vivo tumor growth inhibition in multiple human lymphoma cell lines, with adaptive and innate mechanisms contributing to its anti-tumor activity Non-gene-edited ADI-001 gamma delta CAR T cells demonstrated superior resilience to host versus graft targeting when compared to common gene-edited approaches Excerpt from the Press Release: MENLO PARK,…
SP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain, and it contains no preservatives, surfactants, solvents, or particulates. The study met its primary endpoint with a highly statistically significant reduction in average daily leg pain in patients receiving SEMDEXATM compared to placebo (p<0.001).…
An analysis using the rank-preserving structural failure time model (RPSFTM), a method frequently employed in oncology to account for placebo crossover, estimated a 10.6-month longer median survival duration for AMX0035 participants Participants randomized to receive AMX0035 and who continued into the open-label extension (OLE) phase showed an 18.8-month longer median survival duration than participants who…
Research with renowned oncology expert Dr. Linda Carlson will assess feasibility of a virtual reality guided mindfulness program Excerpt from the Press Release: BOSTON, May 5, 2022 /PRNewswire/ — Rocket VR Health, a digital therapeutics company developing immersive therapy programs, is pleased to announce a new study in partnership with Dr. Linda Carlson, Enbridge Research Chair…
News Summary: Waters opens its newest innovation and research laboratory at University of Delaware (UD) Science, Technology and Advanced Research (STAR) campus Immerse™ Delaware brings together students, faculty, and Waters scientists with industry research partners to identify and address significant challenges facing the biopharmaceutical industry Lab opening milestone is part of multi-year Waters-UD research partnership…
Abelacimab is a dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high affinity and selectivity Robust phase 3 clinical program includes two complementary trials (ASTER and MAGNOLIA) that will enroll ~2700 patients to study abelacimab in patients with Cancer Associated Thrombosis (CAT) The ASTER study will compare abelacimab against the most widely…
Clinical program advancement represents key milestone for Aulos as a clinical-stage company and AU-007’s potential as a novel cancer treatment Excerpt from the Press Release: LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced it has dosed the first patient in a…
Three-month data from ARCT-154 booster trial show persistent neutralizing antibody activity against multiple variants of SARS-CoV-2 International pivotal Phase 3 booster trial preparations initiated with global CRO Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Please replace the graphic with the accompanying corrected graphic. The release reads: ARCTURUS REPORTS STRONG THREE-MONTH DURABILITY RESULTS FROM ARCT-154 BOOSTER…